The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
After six years of cuts to local authority budgets, the money simply isn't there to fund every request for adult social care.
South Carolina residents were told to remain alert to new dangers amid fears more dams in the area could burst as the death toll rose to 16.
As the upcoming film Suffragette is about to be released, ITV News speaks to the family of one of the key figures in the movement.